drugset
drugset / Trial / NCT03606694

Effect of Dihydromirycetin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes Mellitus

NCT03606694 ↗

Phase 2 Unknown 24 enrolled University of Guadalajara
RandomizedParallel-groupDouble-blindTreatment

Summary

Dihydromyricetin has demonstrated promising effects in glycemic control, insulin sensitivity and insulin secretion, that above mentioned findings show that dihydromyricetin has an excellent potential effect in the treatment of type 2 diabetes mellitus patients.

Timeline

Start
2019-10-30
Primary completion
2022-12-28
Completion
2023-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject AMPELOPSIN Small molecule 300 mg —
Subject Metformin Small molecule 850 mg —

Indications

type 2 diabetes mellitus